LOS ANGELES, CA--(Marketwired - Dec 12, 2016) - Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a leading manufacturer of a key
protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases,
will host a conference call and live webcast on Thursday, December 15, 2016 at 1:30 p.m. ET (10:30 a.m. PT) to discuss its fiscal
year 2016 results and to provide an update on its business.
To access the webcast of the conference call, go to:
https://www.webcaster4.com/Webcast/Page/1359/18766. Questions for management may be submitted via the chat feature of the
live online webcast. Audio of the live teleconference is available by dialing (913) 312-1489. Passcode is 2812115.
An audio replay of the call will be available shortly after the conclusion of the live call, and remain available on the
Stellar website for 30 days.
About Stellar Biotechnologies
Based north of Los Angeles at the Port of Hueneme, Stellar
Biotechnologies, Inc. (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet
Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is
both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and
inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods,
facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade
KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark
of Stellar Biotechnologies.
Follow Stellar:
LinkedIn | Twitter
| Facebook
|
Google+
Stellar Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be
identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would,"
"could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on
these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking
statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and
other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such
risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in
strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental
regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners'
anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and
strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further
risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the
U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made
as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such
statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any
jurisdiction, including the United States.